The Men's Health Stack Audit 2026: Which Combinations Doctors Actually Endorse

The modern men's optimization landscape looks nothing like it did five years ago. Where a man once managed a single prescription, the 2026 reality is a stack: a GLP-1 agonist for metabolic health, testosterone replacement for energy and body composition, a PDE5 inhibitor for sexual function, finasteride for the hairline, and maybe a peptide or two for good measure.

The question isn't whether men are combining these therapies — they clearly are. The question is whether the combinations make medical sense and which ones doctors with actual board certifications endorse versus those pushed by Instagram clinics chasing subscriptions.

The Combinations With Strong Clinical Support

GLP-1 + Testosterone Replacement

This is arguably the most evidence-backed stack in men's optimization. The physiological rationale is straightforward: obesity suppresses testosterone through aromatase activity in adipose tissue, and low testosterone promotes visceral fat accumulation. The loop feeds itself.

Multiple studies published between 2023 and 2025 demonstrate that GLP-1 receptor agonists like semaglutide and tirzepatide can increase endogenous testosterone by 15–30% in obese men simply through fat loss. For men hovering in the borderline-low range (250–400 ng/dL), a GLP-1 medication may eliminate the need for exogenous testosterone entirely.

When both are needed — genuinely low T confirmed by two morning draws plus significant metabolic dysfunction — endocrinologists increasingly recommend starting the GLP-1 first. The reasoning: lose weight, recheck testosterone in 3–6 months, then start TRT only if levels remain clinically low. This sequence avoids committing a man to lifelong TRT when weight loss alone might have resolved the deficiency.

TRT + PDE5 Inhibitor (Tadalafil/Sildenafil)

Testosterone and erectile function are related but not redundant. Approximately 30% of men on TRT still experience ED because their erectile dysfunction has vascular or neurological origins that testosterone doesn't address. Adding daily low-dose tadalafil (2.5–5mg) or on-demand sildenafil is well-supported and pharmacologically safe — these drugs act through entirely different pathways.

The one caveat clinicians flag: both TRT and PDE5 inhibitors can lower blood pressure modestly. Men on antihypertensives should have their prescriber coordinate rather than self-adding.

Finasteride + Minoxidil

The classic hair-loss combination has decades of evidence. Finasteride blocks the conversion of testosterone to DHT (the androgen that miniaturizes hair follicles), while minoxidil stimulates growth through vasodilation and follicle-cycle modulation. Together, they produce better results than either alone — a conclusion supported by multiple randomized trials.

What's newer: the interaction with TRT. Men starting testosterone replacement often notice accelerated hair loss because TRT increases DHT substrate. Dermatologists experienced with optimized men now routinely co-prescribe finasteride alongside TRT if the patient values their hair.

The Combinations That Need Careful Coordination

GLP-1 + ED Medication

No direct pharmacological interaction exists between semaglutide/tirzepatide and PDE5 inhibitors. However, GLP-1 medications can cause dehydration and lower blood pressure, which compounds the hypotensive effect of ED drugs. The clinical guidance: stay hydrated, time ED meds away from injection day nausea peaks, and start at lower ED doses during GLP-1 titration.

An indirect benefit often reported: significant weight loss on GLP-1s frequently improves erectile function on its own, reducing or eliminating the need for ED medication entirely. The SELECT trial's cardiovascular data also supports improved vascular health, which feeds erectile function.

TRT + Finasteride

This combination requires nuance. TRT increases testosterone, which increases the substrate for 5-alpha-reductase, which produces DHT. Finasteride blocks that conversion. In theory, the combination lets a man benefit from higher testosterone levels without the hair-loss penalty.

In practice, it works — but monitoring matters. Finasteride on TRT can cause estradiol to rise more than expected because blocked DHT pathways divert more testosterone toward estrogen. Clinicians managing this combination check estradiol alongside testosterone and DHT at every follow-up.

The Combinations Where Evidence Is Thin

NAD+ Injections Alongside Everything

NAD+ (nicotinamide adenine dinucleotide) has become the most-added supplement on men's clinic menus. The sales pitch — mitochondrial energy, DNA repair, anti-aging — is biochemically plausible. The clinical evidence for injected NAD+ improving outcomes in men already on other therapies is, as of mid-2026, nearly nonexistent in human trials.

This doesn't mean NAD+ does nothing. It means the $200–$400/month add-on fee is buying a molecule with strong preclinical data and almost no published human outcomes when stacked with TRT, GLP-1s, or ED meds. Informed men can make that tradeoff knowingly; the issue is when clinics present it as essential.

Sermorelin/Ipamorelin + TRT

Growth hormone secretagogues sit in a similar evidentiary position. The logic — optimize growth hormone alongside testosterone for better body composition — makes sense mechanistically. The published human data comparing TRT-alone against TRT-plus-secretagogue in non-GH-deficient men remains sparse. The FDA has also tightened regulation on compounded peptides since 2023, making supply chains less predictable.

The Audit Framework: Questions to Ask Your Prescriber

The Bottom Line